Follow The Filings

GMED Globus Medical

Globus Medical earnings company data as of 2:27 PM ET 11/13

  • 1 of 1 EPS beats

History

1 period, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS 1.20 1.23 Beat +2.5%
Rev $792.5M $763.7M Miss -3.6%

Insider trades

Open-market buys and sales by GMED's executives, directors and 10% owners in the last 12 months, from their Form 4s

All GMED insider trades
  • None no insider bought on the open market
  • $9.6M sold by 3 insiders outside a trading plan
  • $6.5M sold by 4 insiders under 10b5-1 plans
  1. James R. Tobin Director
    Sale
    $3.1M 41,666 shares at $75.16 100% of stake
    Traded Nov 10 Filed Nov 12
  2. Ann D. Rhoads Director
    Planned sale
    $425K 5,000 shares at $85.00 12% of stake
    Traded Nov 4 Filed Nov 5
  3. James R. Tobin Director
    Sale
    $2.2M 30,000 shares at $74.58 100% of stake
    Traded Sep 15 Filed Sep 16
  4. Stephen T. Zarrilli Director
    Sale
    $2.2M 25,000 shares at $87.04 100% of stake
    Traded Aug 18 Filed Aug 19
  5. David D. Davidar Director
    Sale
    $2M 25,000 shares at $80.76 4.7% of stake
    Traded Jun 5 Filed Jun 9
  6. Kelly Huller EVP, GC, Corporate Secretary
    Planned sale
    $1.9M 20,000 shares at $94.50 100% of stake
    Traded Feb 25 Filed Feb 27
  7. Kelly Huller EVP, GC, Corporate Secretary
    Planned sale
    $877K 10,000 shares at $87.67 100% of stake
    Traded Feb 12 Filed Feb 17
  8. Kyle Kline CFO
    Planned sale
    $363K 3,594 shares at $101.10 100% of stake
    Traded Jan 8 Filed Jan 12
  9. Leslie V. Norwalk Director
    Planned sale
    $202K 2,000 shares at $101.10 16% of stake
    Traded Jan 8 Filed Jan 12
  10. Leslie V. Norwalk Director
    Planned sale
    $355K 4,000 shares at $88.85 24% of stake
    Traded Dec 12, 2025 Filed Dec 16, 2025
  11. Kyle Kline CFO
    Planned sale
    $1.7M 18,542 shares at $90.00 100% of stake
    Traded Dec 1, 2025 Filed Dec 3, 2025
  12. Kelly Huller SVP, GC, Corporate Secretary
    Planned sale
    $675K 7,500 shares at $90.00 100% of stake
    Traded Nov 25, 2025 Filed Nov 28, 2025
  13. David D. Davidar Director
    Sale
    $2.2M 25,000 shares at $86.00 4.6% of stake
    Traded Nov 12, 2025 Filed Nov 13, 2025
  14. Stephen T. Zarrilli Director
    Sale
    $2.1M 25,000 shares at $84.29 100% of stake
    Traded Nov 11, 2025 Filed Nov 13, 2025
  15. Ann D. Rhoads Director
    Planned sale
    $818K 10,000 shares at $81.80 39% of stake
    Traded Nov 7–10 Filed Nov 10, 2025

Also filed in the last 12 months, not counted as buying or selling: 17 option exercises and 1 gift.

SEC filings

Recent issuer filings from EDGAR, 16 shown.

Filed Form Detail Links
10-Q
8-K 2.02,8.01,9.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
8-K 5.02,5.07,9.01
8-K 2.02,9.01
10-Q
SCHEDULE 13G —
DEF 14A
DEFA14A
SCHEDULE 13G/A —
8-K 5.02,7.01,9.01
8-K 2.02,9.01
10-K

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf